Sai Life Sciences subscription started on Wednesday, December 11, 2024, and will close on December 13, 2024, as per the schedule. The price band is set at ₹522 to ₹549 per share with a face value of ₹1.
Sai Life Sciences IPO Subscription Status
Sai Life Sciences Subscribed over 10.27x on its last day till 5.00 PM on 13th December.
- Sai Life Sciences IPO subscription QIB investors portion is 29.78 times, while NII subscribed 4.99 times and RII investors subscribed 1.39 times.
- The company has received bids for 39,85,59,501 shares against 3,87,94,785 shares on offer on the last day of subscription.
- Sai Life Science IPO subscribed over 10.27x on its last day.
- Sai Life Sciences IPO Subscribed over 1.26x on its second day.
- Sai Life Sciences IPO Subscribed over 0.85x on its first day.
About Sai Life Sciences Company
Established in January 1999, Sai Life Science Limited works with innovative pharma and biotech companies by providing services across drug discovery, development, and manufacturing of small-molecule new chemical entities (NCE). Sai Life Sciences Limited is a contract research, development, and manufacturing organization (CRDMO). The company uses its scientific knowledge and skills to deal with critical healthcare challenges. In the future, they aim to develop medicines to treat conditions that are not curable right now and make a huge difference in the future of healthcare. Their services can be customized according to the customer’s needs, whether it’s a small client, a large biotech company, or a global pharmaceutical company making them adaptable and unstoppable. They are growing more in CRDMO than their competitors by earning revenue CAGR (Compound Annual Growth Rate) and EBITDA CAGR from fiscal year 2022 to 2024. They have always delivered a wide set of NCE development programs for their customers over the past 24 years. Quality, price, and responsiveness are the main 3 key areas where they have shown incredible value to its clients.
Sai Life Sciences Financial Report
The company reported revenue of ₹1,494.27 crores in 2024 against ₹1,245.11 crores in 2023. The company reported a Profit of ₹82.81 crores in 2024 against Profit of ₹9.99 crores in 2023.
Sai Life Sciences IPO GMP:
Sai Life Sciences IPO GMP was ₹15 as of Friday, December 13th. That indicates the IPO is trading at ₹579 with ₹15 premium in the grey market against the issue price of ₹549.
